- Stocks
- Pharma & Healthcare
- Medicamen Organ
Medicamen Organ share price
NSE: MEDIORGPharma & HealthcareDrug Manufacturers - Specialty & Generic
Medicamen Organ at a glance
Medicamen Organ (NSE: MEDIORG) closed at ₹25.45 on 21 Oct 2026. With a market capitalisation of ₹38 Cr, it ranks 3231st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 3.5× trailing earnings, against a return on equity of −14.0% in FY26. Over the past year the share price has fallen 41.8%. Its 52-week range is ₹19.10 (12 Jun 2026) to ₹38.00 (23 Oct 2025); the last close is 33.0% below the high. Promoters held 54.89% of the company as of 9 Jun 2026.
Key numbers
- Market cap
- ₹38 CrRank 3231 on NSE
- P/E (trailing)
- 3.5×
- Price to book
- 0.89×FY26
- ROE
- −14.0%FY26
- ROCE
- −15.3%FY26
- Debt to equity
- 0.5FY26
- Net profit margin
- −14.1%FY26
- Book value / share
- ₹23.61FY26
- 52-week high
- ₹38.0023 Oct 2025
- 52-week low
- ₹19.1012 Jun 2026
- 1-year return
- −41.8%
- RSI (14-day)
- 53.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −4.86% | +6.0% | −0.8% | +1.8% | −41.8% |
Medicamen Organ financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹25 Cr | ₹38 Cr | ₹23 Cr |
| Operating profit | ₹3 Cr | ₹5 Cr | −₹5 Cr |
| Net profit | ₹3 Cr | ₹4 Cr | −₹4 Cr |
| EPS (₹) | ₹3.00 | ₹4.00 | −₹3.00 |
| Cash from operations | −₹4 Cr | −₹5 Cr | −₹5 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Shareholders' equity | ₹15 Cr | ₹29 Cr | ₹29 Cr |
Medicamen Organ shareholding pattern
| Holder | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 24 Jan 2026 | 31 Mar 2026 | 9 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 59.69% | 59.73% | 59.73% | 61.27% | 59.73% | 54.89% |
| Foreign institutions | 0.14% | 0.07% | 0.07% | 0.07% | 0.07% | 0.05% |
| Domestic institutions | 3.76% | 3.79% | 3.69% | 3.55% | 1.64% | 0.00% |
| Non-institutions | 36.41% | 36.41% | 36.51% | 35.12% | 38.56% | 45.05% |
Medicamen Organ vs peers
The listed Pharma & Healthcare companies nearest to Medicamen Organ by market capitalisation.
Ask anything about Medicamen Organ
Pivot answers on the live chart with evidence you can check, and tests strategies against MEDIORG's own history. Try: “Why has MEDIORG moved over the last three months?” · “Backtest a 50-day moving-average crossover on MEDIORG over five years” · “Compare MEDIORG with KMSMEDI on margins and valuation”
Frequently asked questions about Medicamen Organ
What is the share price of Medicamen Organ today?
Medicamen Organ (NSE: MEDIORG) last closed at ₹25.45 on 21 Oct 2026. Its 52-week high is ₹38.00 and its 52-week low is ₹19.10.
What is the market cap of Medicamen Organ?
Medicamen Organ's market capitalisation is ₹38 Cr (₹38 Cr) at the 22 Oct 2026 close, ranking 3231st among the NSE companies Pivot tracks.
What is the P/E ratio of Medicamen Organ?
Medicamen Organ trades at a trailing P/E of 3.5.
What is the ROE and ROCE of Medicamen Organ?
Return on equity was −14.0% in FY26 and return on capital employed was −15.3% in FY26 (consolidated figures).
Is Medicamen Organ a debt-free company?
No. Medicamen Organ's debt-to-equity ratio was 0.5 in FY26, with total debt of ₹1 Cr.
How has Medicamen Organ stock performed over the last year?
Medicamen Organ's share price has fallen 41.8% over the past year, +1.8% over three months and −0.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Medicamen Organ?
As of 9 Jun 2026: promoters 54.89%, foreign institutions 0.05%, domestic institutions 0.00%, non-institutions 45.05%.
Who are Medicamen Organ's competitors?
The listed Pharma & Healthcare companies closest to Medicamen Organ by market cap are KMS Medisurgi, Sandu Pharma, Roopa Ind, Lasa Supergenerics, JFL Life Scienc and Chandra Bhagat.
Is Medicamen Organ a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Medicamen Organ's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MEDIORG against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text